165 related articles for article (PubMed ID: 12655443)
21. [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
Feng JF; Lu JW; Sun XF
Ai Zheng; 2004 Dec; 23(12):1704-6. PubMed ID: 15601565
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
[TBL] [Abstract][Full Text] [Related]
23. [A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
Narahara H; Otani T; Iwanaga T; Okajima K; Katsu K; Sowa M; Kobayashi K; Yasutomi M; Okuno M; Takami M; Ishida T; Yasutake K; Yamamoto H; Taguchi T
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1021-6. PubMed ID: 9644317
[TBL] [Abstract][Full Text] [Related]
24. [Effects of low-dose FP therapy for advanced gastric cancer cases].
Liu X; Gu X; Li Y; Li J; Wang P
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2081-5. PubMed ID: 10584576
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
26. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
[TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
28. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
[TBL] [Abstract][Full Text] [Related]
29. [Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
Suzuki H; Kanou Y; Ooshima H; Kawase J; Kudou J; Mizuno Y; Matsumoto S
Gan To Kagaku Ryoho; 2005 Feb; 32(2):189-93. PubMed ID: 15751631
[TBL] [Abstract][Full Text] [Related]
30. [The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer].
Murase M; Kondo K; Kodera Y; Kiriyama K; Akiyama S; Ito K; Yokoyama Y; Shirasaka T; Takagi H
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1025-8. PubMed ID: 8210252
[TBL] [Abstract][Full Text] [Related]
31. [Low-dose FP therapy for advanced and recurrent gastric cancer].
Yamashita Y; Ohira M; Sowa M; Shirasaka T; Hirakawa K; Chung YS
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1548-53. PubMed ID: 10553411
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
[TBL] [Abstract][Full Text] [Related]
33. [Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Mochizuki F; Tomioka K; Mizuno Y; Sato F; Yamagata T; Nagakawa Y; Kobari Y; Fujii M; Iwai S; Tanaka T
Gan To Kagaku Ryoho; 1995 Jan; 22(1):115-8. PubMed ID: 7826065
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
35. Effects of intermittent 5-fluorouracil and low-dose cisplatin therapy on advanced and recurrent gastric cancer.
Kanetaka K; Enjoji A; Furui J; Nagata Y; Fujioka H; Shiogama T; Miyata A; Kishikawa H; Matsuo S; Iwata T; Kanematsu T; Eguchi S;
Anticancer Res; 2012 Aug; 32(8):3495-9. PubMed ID: 22843936
[TBL] [Abstract][Full Text] [Related]
36. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma.
Tanioka H; Tsuji A; Morita S; Horimi T; Takamatsu M; Shirasaka T; Mizushima T; Ochi K; Kiura K; Tanimoto M
Anticancer Res; 2003; 23(2C):1891-7. PubMed ID: 12820474
[TBL] [Abstract][Full Text] [Related]
38. [Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
Gohongi T; Iida H; Nakai R; Gunji N; Orii K
Gan To Kagaku Ryoho; 2006 Jul; 33(7):989-92. PubMed ID: 16835494
[TBL] [Abstract][Full Text] [Related]
39. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
[TBL] [Abstract][Full Text] [Related]
40. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
